MARKET

SUPN

SUPN

Supernus Pharma
NASDAQ
29.40
+0.53
+1.84%
After Hours: 29.40 0 0.00% 16:13 04/19 EDT
OPEN
28.67
PREV CLOSE
28.87
HIGH
29.53
LOW
28.67
VOLUME
361.63K
TURNOVER
0
52 WEEK HIGH
39.09
52 WEEK LOW
21.99
MARKET CAP
1.61B
P/E (TTM)
1240.51
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at SUPN last week (0408-0412)?
Weekly Report · 6d ago
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Argenx Se (ARGX), Neogen (NEOG) and Supernus Pharmaceuticals (SUPN)
TipRanks · 6d ago
BUZZ-U.S. STOCKS ON THE MOVE-Perpetua Resources, Huntington Bancshares, FuelCell Energy
Wall Street's main stock indexes advanced in choppy trading on Monday. The Dow Jones Industrial Average was up 0.10% at 38,942.47. The top three S&P 500 percentage gainers were Albemarle, Tesla and Tesla. Boeing and Boeing Co were among the biggest decliners.
Reuters · 04/08 18:05
Supernus Pharmaceuticals Shares Slip 6.9% After FDA Says Drug Application Not Ready
Supernus Pharmaceuticals shares are down 6.9% in afternoon trading. The company's new drug application for a device to treat "off" episodes in Parkinson's disease is not ready for approval. The stock is still up about 8% since the start of the year. The FDA says the company's product quality and the infusion device require further review.
Dow Jones · 04/08 17:49
BUZZ-U.S. STOCKS ON THE MOVE-JPMorgan, Ameresco, Copper miners
Wall Street's main stock indexes advanced in choppy trading on Monday. The Dow Jones Industrial Average was up 0.10% at 38,941.91. The top three S&P 500 percentage gainers were Tesla, GE and Ameresco. Treasury yields retreated from session highs as investors awaited the Fed's rate outlook.
Reuters · 04/08 16:11
Supernus Pharmaceuticals Faces Second FDA Rejection For Investigational Device For Parkinson's Disease
Supernus Pharmaceuticals Inc. (NASDAQ: SUPN) announced a regulatory update for SPN-830, an investigational apomorphine infusion device under FDA review for the treatment of motor fluctuations in Parkinson's disease. The FDA has issued a Complete Response Letter in response to the company's New Drug Application for the device. SUPN stock fell as much as 9% during the premarket session.
Benzinga · 04/08 14:11
BUZZ-U.S. STOCKS ON THE MOVE-Ocugen, Model N, Fastly
Futures tracking Wall Street's main indexes were largely muted on Monday. Treasury yields rose on rising bets that the U.S. Federal Reserve could delay interest-rate cuts this year. Dow e-minis were up 0.13% in early trading. Ocugen up 9.8% on FDA approval of gene therapy for Parkinson's disease.
Reuters · 04/08 13:50
Supernus stock slides as FDA rejects Parkinson's disease infusion device
Supernus Pharmaceuticals stock slides as FDA rejects Parkinson's disease infusion device. The U.S. Drug regulator rejected its experimental apomorphine infusion device for the continuous treatment of motor fluctuations associated with Parkinson’s disease. Supernus shares dipped 11% premarket on Monday.
Seeking Alpha · 04/08 12:39
More
About SUPN
Supernus Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson’s Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The Company is also developing a range of novel CNS product candidates, including new potential treatments for hypomobility in PD, epilepsy, depression, and other CNS disorders. Its commercial products, including Qelbree (viloxazine), GOCOVRI (amantadine), Oxtellar XR (oxcarbazepine), Trokendi XR (topiramate), APOKYN (apomorphine hydrochloride injection) and others. Qelbree (viloxazine) is a novel non-stimulant product indicated for the treatment of ADHD.

Webull offers Supernus Pharmaceuticals Inc stock information, including NASDAQ: SUPN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SUPN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SUPN stock methods without spending real money on the virtual paper trading platform.